Tenecteplase on Par With Alteplase, Randomized Trial Affirms

(MedPage Today) -- DALLAS -- Tenecteplase (TNKase) did as good a job at ischemic stroke thrombolysis as did alteplase (Activase) for patients presenting within 4.5 hours of symptom onset in the randomized TRACE-2 trial from China. The proportion...

https://www.medpagetoday.com/meetingcoverage/isc/103038

Source: MedPage Today Cardiovascular - February 9, 2023 Category: Cardiology Source Type: news